Delays in epidermal growth factor receptor mutation (EGFRm) testing in advanced (stage IIIb/ IIIc/ IV) non-small cell lung cancer (NSCLC) patients and their impact on the use of first line tyrosine kinase inhibitor (TKIs) in a real-world setting: [abstract] 144P

Medientyp: E-Artikel
Titel: Delays in epidermal growth factor receptor mutation (EGFRm) testing in advanced (stage IIIb/ IIIc/ IV) non-small cell lung cancer (NSCLC) patients and their impact on the use of first line tyrosine kinase inhibitor (TKIs) in a real-world setting : [abstract] 144P
Beteiligte: Griesinger, Frank [Verfasser:in]; Choi, Y. [Verfasser:in]; Chou, T. [Verfasser:in]; Gregg, J. [Verfasser:in]; Hui, R. [Verfasser:in]; Leighl, N. [Verfasser:in]; Marchetti, A. [Verfasser:in]; Navani, N. [Verfasser:in]; Bailey, T. [Verfasser:in]; Silvey, M. [Verfasser:in]
Erschienen: 2021
Erschienen in: Journal of thoracic oncology ; 16(2021), 4, Supplement, Seite S775-S776
Sprache: Englisch
DOI: 10.1016/S1556-0864(21)01986-9
Identifikator:

Nur in Feld suchen: